Stockreport

AbbVie's Immunology Fortress Can't Hide Cracks In Diversification (Downgrade) [Seeking Alpha]

AbbVie Inc.  (ABBV) 
Last abbvie inc. earnings: 5/1 07:43 am Check Earnings Report
US:NYSE Investor Relations: investors.abbvie.com/investor-overview
PDF ABBV's Q4 2025 saw 18% Immunology growth and 10% total revenue growth, but Oncology and Aesthetics portfolios declined, highlighting diversification challenges. 2026 [Read more]